Tildrakizumab linked to improved outcomes in plaque psoriasis patients

Almirall, a global biopharmaceutical company specializing in medical dermatology, has announced significant progress in the treatment of moderate-to-severe plaque psoriasis with their drug, Ilumetri® (tildrakizumab). The positive results were presented at the 25th World Congress of Dermatology held in Singapore.

In the preliminary analysis of the POSITIVE study, tildrakizumab demonstrated a substantial improvement in the wellbeing of patients with moderate-to-severe plaque psoriasis. After 16 weeks of treatment, patients achieved a level of wellbeing comparable to that of the general population, which was maintained up to week 28. The study also revealed significant improvements in skin symptoms and health-related quality of life (HRQoL) among patients. Moreover, the safety profile of tildrakizumab remained consistent with previous randomized clinical trials, with no new safety concerns observed.

One noteworthy finding from the study was the revelation that the baseline wellbeing level of patients with moderate-to-severe plaque psoriasis was comparable to that of individuals with other diseases, including breast cancer. This insight highlights the substantial impact that psoriasis can have on a patient's overall wellbeing.

The POSITIVE study, a groundbreaking clinical trial in dermatology, assessed patients' wellbeing as the primary endpoint using the World Health Organization Wellbeing Index (WHO-5). This widely-used questionnaire evaluates subjective psychological wellbeing and provides a comprehensive understanding of the impact of psoriasis and its treatment on patients' lives. By incorporating a holistic and person-centered approach to assessing wellbeing, the study aims to enhance patient-clinician relationships and improve treatment outcomes.